Patients were seen at entry for baseline measurements and assessments and thereafter at months 1, 4, and 7. Baseline assessments included a medical history and a blood sample to assay gonadotrophin concentrations.The number and severity of flushing and sweating episodes (day and night) were documented daily on the diary cards, as well as details of any adverse effects.The change in the number of daytime and night time episodes of flushing and sweating between the initial control cycle and the last available treatment cycle was calculated for each subject. The significance of the improvement was assessed by the Wilcoxon signed ranks test. Differences between groups were assessed by the Mann-Whitney U test.